<DOC>
	<DOCNO>NCT00390364</DOCNO>
	<brief_summary>RATIONALE : Everolimus may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well everolimus work treat patient advanced metastatic colorectal cancer respond previous therapy .</brief_summary>
	<brief_title>Everolimus Treating Patients With Advanced Metastatic Colorectal Cancer That Did Not Respond Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate , time tumor progression , survival patient advance metastatic refractory colorectal cancer mutation PI3K gene treat everolimus . - Determine toxicity profile drug patient . - Measure signal pathway activate patient . - Determine pharmacodynamic effect drug patient . OUTLINE : This open-label study . Patients receive oral everolimus daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo tumor biopsy normal skin biopsy baseline first course study treatment . Tumor tissue examine biological marker ( e.g. , epidermal growth factor receptor , ERK , Akt , p70s6k , p27 , Rb protein ) immunohistochemistry ; apoptosis quantification TUNEL assay ; Ki-67 quantification Ki-index ; gene expression ; c-fos p27 expression reverse-transcriptase polymerase chain reaction . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically pathologically confirm colorectal adenocarcinoma Advanced metastatic disease Refractory ≥ 1 line prior therapy Not amenable potentially curative surgical resection Mutations PI3K gene tumor tissue Tumor tissue available genetic testing OR willing undergo baseline tumor biopsy Tumor amenable sequential biopsy Willing undergo 2 sequential tumor biopsy , 2 sequential skin biopsy Measurable lesion ≥ 1 diameter ≥ 2 cm conventional CT scan ( 1 cm spiral CT scan ) nonirradiated area No known brain metastasis PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % Life expectancy &gt; 12 week WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) Creatinine normal OR creatinine clearance ≥ 60 mL/min Cholesterol triglycerides ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction attribute compound similar chemical biologic composition everolimus No uncontrolled intercurrent illness , include , limited , follow : Hypertension Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No evidence bleed diathesis Able swallow tablet PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior radiotherapy chemotherapy ( 6 week nitrosoureas mitomycin C ) recover No prior target therapy mTOR No concurrent investigational agent No concurrent therapeutic anticoagulation Prophylactic anticoagulation ( i.e. , lowdose warfarin ) venous arterial access device allow provided requirement PT , INR PTT meet . No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy , include chemotherapy , hormonal therapy , immunotherapy , alternative therapy , radiotherapy No concurrent live vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>